Foundayo (orforglipron), a recent GLP-1 option, permits intake anytime without the need for mealtime planning, thus offering greater flexibility
Novo Nordisk, the company who produces Ozempic, has the patent until 2033, when it will expire
No customs step, no border delays and because it never leaves Ireland
That is why it is risky to equate every drop in lean mass with clinically meaningful muscle loss, especially when comparing results across different body-composition methods, since these methods are not directly interchangeable and may estimate fat and lean mass differently
Use the medicine exactly as directed, especially during starting, restarting, or dose changes, because rapid changes can increase the risk of serious skin reactions